TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03192475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GLB plus phone contacts
Description: GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The active treatment group also receives 8 additional group phone conference calls for social support and problem solving.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: GLB plus newsletter contacts
Description: GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The placebo comparator includes 4 additional newsletters only.
Study: NCT02690753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A protocol tailored to individual risk factors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Prevalon® Turn and Position System 2.0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Prevalon® Turn and Position System 2.0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort Shield® barrier cream cloths

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort Shield® barrier cream cloths
Study: NCT01792791

Intervention type: PROCEDURE
Intervention: Tissue sample collection at the time of surgery
Description: Spanning surgery~* A blood sample (32.5 ml)~* joint aspirate (removal of synovial fluid) from both knees~* urine sample~ORIF surgery~* Joint aspirate (removal of synovial fluid) from both knees~* A blood sample (32.5 ml)~* Urine Sample~If patients only require one surgery, sample will be collected only once.
Study: NCT03219957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: Ascending doses of AT-527 administered orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Matching placebo
Study: NCT02343289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: 28 mg of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, 84 mg of intranasal esketamine on Day 1 of Period 3 and on Day 1 of Period 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
Study: NCT02179086

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo standard-dose 3D-CRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo standard-dose 3D-CRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: Undergo standard-dose IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: Undergo standard-dose IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: photon beam radiation therapy
Description: Undergo dose-escalated and -intensified photon IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo dose-escalated and -intensified photon IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam radiation therapy
Description: Undergo dose-escalated and -intensified proton beam radiation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00867464

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Long-term Follow-up
Description: Undergo extended follow-up

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04294199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Range of MOtion
Description: Groups will be compared to see if immobilization or early range of motion is better at returning to their sport after patellar dislocation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Range of MOtion
Description: Groups will be compared to see if immobilization or early range of motion is better at returning to their sport after patellar dislocation.
Study: NCT02658669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia
Description: Intervention includes strategies designed to improve sleep such as: sleep restriction, stimulus-control techniques, sleep hygiene education, and relaxation training.
Study: NCT02448329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1\~3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80 mg/m2 given days 1, 8 and 15 of a 28 day cycle
Study: NCT03349151

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early feeding
Description: Feeding on postoperative 2nd hour on return to the ward

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: On- Demand feeding
Description: Feeding whenever the patient asks for on return to the ward
Study: NCT03444896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Description: Acupuncture needles were placed at acupoints Baihui (DU20), Shenting (DU24), Fengfu (DU16), Fengchi (GB20), Danzhong (RN17), Zhongwan (RN12), Qihai (RN6), Neiguan (PC6), Zusanli (ST36), Xuehai (SP10), Xinshu (BL15), Yixi (BL45), Tongli (HT5), and Zhaohai(KI6). Electrodes were attached the needle holders of the Baihui (DU20) and Shenting (DU24). The acupuncture needles are inserted through the adhesive pads and are retained for 20 minutes in every course. Treatment will be conducted over a period of 3 months, at a frequency of two times per week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture group
Description: Sham acupoint (SA) 1 located in the midpoint of Shuaigu and Touwei. SA2 located in the midpoint of Touwei and Yangbai. SA3 located in the midpoint of Tianyou and Tianrong. SA4 located in 4 cun above umbilicus and 1 cun right of umbilical midline (UM). SA5 located in 2 cun below umbilicus and 1 cun right of UM. SA6 1 cun outside the point 1/4 of the line between Shenmen and Shaohai. SA7 located in 1 cun outside the midpoint of Shaohai and Tongli. SA8 located in 6 cun above mediosuperior border of the patella. SA9 located in 3 cun below the Yanglingquan and middle of the gallbladder and bladder channels. SA10 located in midpoint between Jiexi and Qiuxu. SA11 and SA12 located in 2 cun from the lower border of spinous process of fifth or sixth thoracic vertebra. Electrodes were attached the needle holders of the bilateral SA 2. Procedures, and other treatment settings were the same in the acupuncture group but with no skin penetration, electricity output, or needle manipulation for de qi.
Study: NCT00371098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination: Influvac (SolvayPharma)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo influenza vaccine
Study: NCT02084199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: 100 mg oral tablet, intake once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: 100 mg oral tablet, intake once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: 100 mg oral tablet, intake once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: 100 mg oral tablet, intake once daily for 10 days
Study: NCT02658669

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: Intervention includes sleep hygiene education and education regarding the impact of TBI on sleep.
Study: NCT02084199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: 100 mg oral tablet, intake once daily for 10 days
Study: NCT03970538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LimFlow System
Description: Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia
Study: NCT03613025

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sampling of non-invasive and/or non-targeted respiratory tract specimens
Description: Sampling of oral fluids, sputa, bronchial aspiration in addition to BAL for the molecular diagnosis of PCP

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sampling of non-invasive and/or non-targeted respiratory tract specimens
Description: Sampling of oral fluids, sputa, bronchial aspiration in addition to BAL for the molecular diagnosis of PCP
Study: NCT04114669

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: 3 in-person study visits, approximately one hour each. These will take place at baseline, 6 months, and 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regret Lottery
Description: Delivered by the Way to Health platform, installed on a smartphone and communicates with participants via text message.Participants are eligible to receive a potential cash reward if they are adherent with their antihypertensive medication the day before, which is monitored via electronic monitoring device (EMD) from AdhereTech. Each participant is assigned a 2-digit number for the trial, and each day the Way to Health platform randomly generates a 2-digit number. Participants will receive a prize if both digits match (1 in 100 chance) and will receive a prize of lesser value if one digit matches (18 in 100 chance). If they are not adherent with their medication, but would have won if they were adherent, they receive a text message that they would have won (regret component).
Study: NCT03099577

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 1
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 2
Description: concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 3
Description: concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 4
Description: concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 5
Description: concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 6
Description: concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 7
Description: concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
Study: NCT03075748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAAA Debranching Stent Graft System
Description: The TAAA Debranching Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components. The two custom main body grafts are the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAAA Debranching Stent Graft System
Description: The TAAA Debranching Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components. The two custom main body grafts are the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
Study: NCT02446444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional NSAA
Study: NCT03997383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patisiran
Description: Patisiran will be administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patisiran
Description: Patisiran will be administered by intravenous (IV) infusion.
Study: NCT02446444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRHA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHA

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)
Study: NCT01733121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 25 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 50 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03128619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Breast
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Breast
Description: Undergo biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03791762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WaveOne Gold
Description: WaveOne Gold was operated by an endomotor (VDW Gold, Munich, Germany) at WaveOne ALL setting.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc Blue
Description: Reciproc Blue was operated by an endomotor (VDW Gold, Munich, Germany) at Reciproc ALL setting.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ProTaper Next
Description: ProTaper Next was operated by an endomotor (VDW Gold, Munich, Germany) with 16:1 contra angle at the settings suggested by the manufacturer (350 rpm, 3 Ncm).
Study: NCT02521792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
Study: NCT04237545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T3 short and restoration (prosthesis)
Description: A qualified patient will be treated with a T3 short implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T3 standard length and restoration (prosthesis)
Description: A qualified patient will be treated with a T3 standard length implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
Study: NCT04718480

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: po fluvoxamine tablets
Study: NCT00635544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment
Description: dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary treatment
Description: dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
Study: NCT00426764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
Study: NCT04346576

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics prevent health problems in children
Description: A controlled field trial was conducted with 1,036 children (3-5 years old) in Thanh Hoa province in Vietnam. The probiotic group (n=518) consumed fermented milk 65 mL/day containing 108 CFU/mL of LcS for the 12-week intervention period, whereas the control group (n=493) were not given any. The incidence of constipation, diarrhea, ARI, and anthropometry in children was determined at baseline, after 4, 8, and 12-week intervention and after the 4-week follow-up period.
Study: NCT02894814

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-Stop Dispensing
Description: Use of own medication, review of the patient's medication, partly or self-administration of medication during hospitalization under support from the health personnel to improve adherence, knowledge and feeling safe about the medication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-Stop Dispensing and focused dialogue
Description: Besides the elements of One-Stop Dispensing focused dialogue about the patient's medicine during hospitalization and at discharge to improve adherence, knowledge and feeling safe about the medication
Study: NCT04010292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education card
Description: Patient who are randomized to receive a patient card at the end of the counseling visit will be able to take an index-card sized card with them which will highlight their anticipated surgery.
Study: NCT01188668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Period 1-Aripiprazole 5mg on study day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole + desvenlafaxine succinate sustained release
Description: Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
Study: NCT01585246

Intervention type: DRUG
Group type: OTHER
Intervention: Saw Palmetto
Description: 1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saw Palmetto
Description: 1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)